Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Prostate Cancer: Which Guidelines

March 19th 2015

Changes in NCCN Guideline: Affecting First-Line

March 19th 2015

Considerations in Treatment Selection

March 19th 2015

Sipuleucel-T: Evidence-based Use

March 19th 2015

Changes in NCCN Guideline: Affecting Second-Line

March 19th 2015

A Review of Bone-Targeted Therapies

March 19th 2015

Sequencing: Important Question With Many Answers

March 19th 2015

Abiraterone: Approval and Use

March 19th 2015

MAINSAIL: Lessons Learned

March 19th 2015

Looking Forward: Immunotherapy and Genomics

March 19th 2015

When to Image: Earlier?

March 19th 2015

Dr. Koo on Active Surveillance Rates in Prostate Cancer

March 19th 2015

Alec Koo, MD, FACS, managing partner, Skyline Urology, board of directors, LUGPA, discusses results from a recent study on active surveillance in prostate cancer.

Gomella Discusses Optimizing Sipuleucel-T in mCRPC

March 16th 2015

In an interview with OncLive, Leonard G. Gomella discusses the benefits, limitations, and considerations of sipuleucel-T for patients with prostate cancer.

Dr. Benson on Challenges of Active Surveillance for Prostate Cancer

March 16th 2015

Mitchell Benson, MD, the Herbert and Florence Irving Professor at Columbia University Medical Center, New York-Presbyterian Hospital, discusses potential issues with active surveillance for patients with intermediate-risk prostate cancer.

Dr. Dreicer on Sequencing Therapies for Patients with Prostate Cancer

March 16th 2015

Robert Dreicer, MD, MS, FACP, FASCO, Division of Hematology and Oncology, Department of Medicine, University of Virginia School of Medicine, discusses sequencing therapies in prostate cancer.

Dr. Higano on Radium-223 for mCRPC

March 16th 2015

Celestia S. Higano, MD, FACP, professor of medicine and urology, University of Washington, discusses radium-223 chloride and its efficacy for patients with metastatic castration-resistant prostate cancer (mCRPC).

Task Force PSA Recommendation Needs Updating, LUGPA President Says

March 16th 2015

A United States Preventive Services Task Force recommendation against the use of prostate specific antigen testing needs to be updated, said Gary Kirsh, MD, president of the Large Urology Group Practice Association.

Making Sense of the Prostate Cancer Screening Debate

March 14th 2015

Leonard G. Gomella, MD, told attendees at the 8th Annual IPCC that the decision to screen or not to screen for prostate cancer boiled down to "using common sense, shared decision making, and choosing the right patients to screen."

Proceed With Caution Is the Message on Active Surveillance

March 14th 2015

Physicians should engage in careful patient selection before recommending active surveillance for prostate cancer, according to Mitchell C. Benson, MD.

Noted Astronaut Addresses Importance of Teamwork at Prostate Congress

March 14th 2015

In a similar fashion as astronauts, physicians can mitigate risks and improve outcomes with advanced planning and teamwork, four-time space shuttle commander Tom Henricks said during his keynote address at the Interdisciplinary Prostate Cancer Congress.